CRISPR/Cas9 knockout of IKK1/2, a regulation factor complex in NF-kB signaling, leads to TNFα-induced cell death in HEK293 (human embryonic kidney cells) suggesting that IKK1/2 targeting could become a promising strategy in cancer therapy, in order to treat tumor cells resistant to TNFα-induced cell death [57]. This evidence concerns the gene TNF and neoplasm.